Experienced in Lynch Syndrome

Dr. Douglas A. Levine

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
1275 York Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Lynch Syndrome
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Douglas Levine is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Levine is rated as an Experienced provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Oophorectomy, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 217 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lynch Syndrome.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

1275 York Ave, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
WISP (Women Choosing Surgical Prevention)
WISP (Women Choosing Surgical Prevention)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Poly ICLC
Study Phase: Phase 1/Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 10, 2020
View 5 Less Clinical Trials

217 Total Publications

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.
Journal: Cell
Published: November 04, 2025
Similar Doctors
Elite in Lynch Syndrome
Dr. Zsofia K. Stadler
Hematology Oncology | Oncology
Elite in Lynch Syndrome
Dr. Zsofia K. Stadler
Hematology Oncology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zsofia Stadler is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Stadler is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. Her top areas of expertise are Lynch Syndrome, Colorectal Cancer, Familial Colorectal Cancer, Colonoscopy, and Endoscopy. Dr. Stadler is currently accepting new patients.

Elite in Lynch Syndrome
Dr. Kenneth Offit
Oncology
Elite in Lynch Syndrome
Dr. Kenneth Offit
Oncology

Memorial Clinical Genetics Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Offit is an Oncologist in New York, New York. Dr. Offit has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Breast Cancer, Lynch Syndrome, Ovarian Cancer, Salpingo-Oophorectomy, and Prostatectomy. Dr. Offit is currently accepting new patients.

Elite in Lynch Syndrome
Dr. David J. Gallagher
Oncology
Elite in Lynch Syndrome
Dr. David J. Gallagher
Oncology
1233 York Ave, Apartment 21n, 
New York, NY 
 (0.1 miles away)
917-257-8237
Languages Spoken:
English

David Gallagher is an Oncologist in New York, New York. Dr. Gallagher is rated as a Distinguished provider by MediFind in the treatment of Lynch Syndrome. His top areas of expertise are Lynch Syndrome, Colorectal Cancer, Anal Cancer, Breast Cancer, and Vitrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levine's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile